secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K/A
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001104659-25-100456
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics creates CVRs entitling holders to 50% of net proceeds from TTX-MC138 asset sales
--------------------------------------------------------------------------------

- Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.
- CVR term is 7 years from Oct 8, 2025; distributions paid quarterly within 60 days after each quarter end, starting with Q4 2025 if proceeds are received.
- CVRs are non-transferable except by Permitted Transfers (inheritance, court order, merger); no certificates, book-entry only via DTC.
- Vstock Transfer, LLC appointed as Rights Agent; Company must deliver payment statement and funds to Rights Agent within 60 days of each quarter.
- Net Proceeds = Gross Proceeds minus Permitted Deductions (taxes, out-of-pocket costs, business development expenses, etc.).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925100456/0001104659-25-100456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925100456/tm2528999d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-100456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer